Production / Operations
The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch
Precision Peptide Clears Purity Hurdle, But Commercial Execution Risks Remain
Executive Summary
- The company released independent third-party laboratory results confirming 95.5% chromatographic purity for its lead product candidate, a needle-free BPC-157 transdermal patch.
- Testing was conducted by Miraxis Labs using UHPLC-DAD methods, exceeding the $\ge$95% industry benchmark for high-purity grade peptide products.
- The quantified dose is confirmed at 2.02 mg of BPC-157 per patch.
- Regulatory context indicates the FDA Pharmacy Compounding Advisory Committee will evaluate BPC-157 for inclusion on the 503A Bulks List on July 23, 2026.
- The company intends to progress toward commercial release subject to additional testing and manufacturing scale-up.
- This news follows a strategic marketing partnership announced May 12 with Mixed Martial Arts Group Limited (MMA) to market peptide products to MMA's global ecosystem.
Material Impact
- Validation of Product Viability: The independent lab results de-risk the commercial launch by confirming quality standards are met, which is critical for consumer trust in a wellness/peptide product.
- Incremental vs. New Information: While positive, this news was anticipated following the May 7 update stating "results expected in the near term." It confirms execution rather than introducing a new strategic pivot like the MMA partnership did on May 12.
- Revenue Catalyst Linkage: The purity data supports the validity of the revenue-generating vertical established with MMA, but does not itself generate immediate cash flow.
- Regulatory Dependency: Commercial launch remains contingent on the July 23 FDA PCAC evaluation; this news clears a quality hurdle but not the regulatory one.
- Market Expectation: The stock price has already reacted to the May 12 partnership (rising to $0.51), suggesting some of the commercial optimism is priced in, making this validation routine rather than game-changing.
BPC · Price
Company Overview
- Company: The Precision Peptide Company Inc. (CSE: BPC).
- Flagship Project: Needle-free BPC-157 transdermal patch designed to eliminate injections, reconstitution, and sterile handling barriers for peptide therapy.
- Subsidiary: Amino Innovations manages the existing oral peptide line and the new delivery technology platform.
- Development Stage: Lead product has cleared independent purity testing; awaiting regulatory inclusion on FDA 503A Bulks List for commercial launch.
- Second Product: Immune Defense Patch (Thymosin Alpha-1) is in development on the same delivery platform.
More from The Precision Peptide Company Inc.
Jun 23, 2026 · 07:31